These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12392585)

  • 21. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
    Clin Drug Investig; 2003; 23(10):629-37. PubMed ID: 17535078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
    Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
    Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
    Enimil A; Antwi S; Yang H; Dompreh A; Alghamdi WA; Gillani FS; Orstin A; Bosomtwe D; Opoku T; Norman J; Wiesner L; Langaee T; Peloquin CA; Court MH; Greenblatt DJ; Kwara A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
    Cammett AM; MacGregor TR; Wruck JM; Felizarta F; Miailhes P; Mallolas J; Piliero PJ
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4147-52. PubMed ID: 19620337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
    Vogel M; Bertram N; Wasmuth JC; Wyen C; Voigt E; Schwarze-Zander C; Sudhop T; Fätkenheuer G; Rockstroh JK; Reichel C
    J Antimicrob Chemother; 2009 May; 63(5):988-91. PubMed ID: 19270314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
    von Hentig N; Carlebach A; Gute P; Knecht G; Klauke S; Rohrbacher M; Stocker H; Kurowski M; Harder S; Staszewski S; Haberl A
    Br J Clin Pharmacol; 2006 Nov; 62(5):552-9. PubMed ID: 17061962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
    Jullien V; Tréluyer JM; Chappuy H; Dimet J; Rey E; Dupin N; Salmon D; Pons G; Urien S
    Br J Clin Pharmacol; 2005 Feb; 59(2):183-8. PubMed ID: 15676040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
    Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could pharmacogenetics aid the prediction of nevirapine pharmacokinetics and allow individualized treatment?
    Kwara A
    Pharmacogenomics; 2021 Sep; 22(14):881-884. PubMed ID: 34505542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
    Micheli JE; Chinn LW; Shugarts SB; Patel A; Martin JN; Bangsberg DR; Kroetz DL
    Pharmacogenet Genomics; 2013 Nov; 23(11):591-6. PubMed ID: 23982262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of nevirapine dosing recommendations in HIV-infected children.
    Foissac F; Bouazza N; Frange P; Blanche S; Faye A; Lachassinne E; Dollfus C; Hirt D; Benaboud S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2013 Jul; 76(1):137-44. PubMed ID: 23278548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
    Svensson E; van der Walt JS; Barnes KI; Cohen K; Kredo T; Huitema A; Nachega JB; Karlsson MO; Denti P
    Br J Clin Pharmacol; 2012 Sep; 74(3):465-76. PubMed ID: 22300396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.